Beata Halassy

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1134523/publications.pdf

Version: 2024-02-01

62	722	516710 16	677142 22
papers	citations	h-index	g-index

63	63	63	799
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Venomics of Vipera berus berus to explain differences in pathology elicited by Vipera ammodytes ammodytes envenomation: Therapeutic implications. Journal of Proteomics, 2016, 146, 34-47.	2.4	47
2	Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specific immune response. Vaccine, 2009, 27, 5435-5442.	3.8	33
3	Concentration and purification of rubella virus using monolithic chromatographic support. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 981-986.	2.3	32
4	Recovery of infective virus particles in ion-exchange and hydrophobic interaction monolith chromatography is influenced by particle charge and total-to-infective particle ratio. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1054, 10-19.	2.3	29
5	Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine, 2003, 21, 971-976.	3.8	23
6	Effect of Liposomal Formulations and Immunostimulating Peptidoglycan Monomer (PGM) on the Immune Reaction to Ovalbumin in Mice. Journal of Liposome Research, 2006, 16, 1-16.	3.3	23
7	Influence of charge ratio of liposome/DNA complexes on their size after extrusion and transfection efficiency. International Journal of Nanomedicine, 2012, 7, 393.	6.7	23
8	COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?. Transfusion Clinique Et Biologique, 2021, 28, 264-270.	0.4	23
9	Stability, biophysical properties and effect of ultracentrifugation and diafiltration on measles virus and mumps virus. Archives of Virology, 2016, 161, 1455-1467.	2.1	22
10	Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits. Vaccine, 2007, 25, 3475-3481.	3.8	20
11	VaH3, one of the principal hemorrhagins in Vipera ammodytes ammodytes venom, is a homodimeric P-IIIc metalloproteinase. Biochimie, 2013, 95, 1158-1170.	2.6	20
12	Vipera ammodytes bites treated with antivenom ViperaTAb: a case series with pharmacokinetic evaluation. Clinical Toxicology, 2017, 55, 241-248.	1.9	20
13	Immunomodulatory activity of novel adjuvant formulations based on Montanide ISA oil-based adjuvants and peptidoglycan monomer. International Immunopharmacology, 2008, 8, 717-724.	3.8	19
14	Ammodytagin, a heterodimeric metalloproteinase from Vipera ammodytes ammodytes venom with strong hemorrhagic activity. Toxicon, 2011, 58, 570-582.	1.6	18
15	Immunogenicity of peptides of measles virus origin and influence of adjuvants. Vaccine, 2006, 24, 185-194.	3.8	17
16	Identification of proteins interacting with ammodytoxins in Vipera ammodytes ammodytes venom by immuno-affinity chromatography. Analytical and Bioanalytical Chemistry, 2014, 406, 293-304.	3.7	17
17	Refinement strategy for antivenom preparation of high yield and quality. PLoS Neglected Tropical Diseases, 2019, 13, e0007431.	3.0	17
18	Hemorrhagin VaH4, a covalent heterodimeric P-III metalloproteinase from Vipera ammodytes ammodytes with a potential antitumour activity. Toxicon, 2014, 77, 141-155.	1.6	15

#	Article	IF	Citations
19	Paraspecificity of Vipera a. ammodytes-specific antivenom towards Montivipera raddei and Macrovipera lebetina obtusa venoms. Toxicon, 2014, 78, 103-112.	1.6	15
20	The variability of Vipera ammodytes ammodytes venoms from Croatiaâ€"biochemical properties and biological activity. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2005, 140, 257-263.	2.6	14
21	Comparative study of structurally related peptidoglycan monomer and muramyl dipeptide on humoral IgG immune response to ovalbumin in mouse. International Immunopharmacology, 2010, 10, 751-759.	3.8	14
22	Nonspecific native elution of proteins and mumps virus in immunoaffinity chromatography. Journal of Chromatography A, 2016, 1447, 107-114.	3.7	14
23	Investigation of the thermal shift assay and its power to predict protein and virus stabilizing conditions. Journal of Pharmaceutical and Biomedical Analysis, 2018, 161, 73-82.	2.8	14
24	The standard mouse assay of anti-venom quality does not measure antibodies neutralising the haemorrhagic activity of Vipera ammodytes venom. Toxicon, 2012, 59, 709-717.	1.6	12
25	Compassionate mesenchymal stem cell treatment in a severe COVID-19 patient: a case report. Croatian Medical Journal, 2021, 62, 288-296.	0.7	12
26	ChAdOx1â€š adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. European Journal of Immunology, 2022, 52, 936-945.	2.9	12
27	Intraspecies variability in Vipera ammodytes ammodytes venom related to its toxicity and immunogenic potential. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2011, 153, 223-230.	2.6	11
28	A Single Dose of ViperfavTM May Be Inadequate for Vipera ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation. Toxins, 2016, 8, 244.	3.4	11
29	Stability of Minimum Essential Medium functionality despite l-glutamine decomposition. Cytotechnology, 2016, 68, 1171-1183.	1.6	11
30	The role of antibodies specific for toxic sPLA2s and haemorrhagins in neutralizing potential of antisera raised against Vipera ammodytes ammodytes venom. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2008, 148, 178-183.	2.6	10
31	Studying disulfide bond rearrangement by MALDIâ€RTOF PSD and MALDIâ€TOF/RTOF highâ€energy CID (20 keV) experiments of peptides derived from ammodytoxins. Journal of Mass Spectrometry, 2011, 46, 153-162.	1.6	10
32	Mass spectrometry-based investigation of measles and mumps virus proteome. Virology Journal, 2018, 15, 160.	3.4	10
33	Determination of DNA entrapment into liposomes using short monolithic columns. Journal of Chromatography A, 2007, 1144, 150-154.	3.7	9
34	Robustness testing of live attenuated rubella vaccine potency assay using fractional factorial design of experiments. Vaccine, 2010, 28, 5497-5502.	3.8	9
35	Structural and biochemical characterisation of VaF1, a P-IIIa fibrinogenolytic metalloproteinase from Vipera ammodytes ammodytes venom. Biochimie, 2015, 109, 78-87.	2.6	9
36	Identification of mumps virus protein and lipid composition by mass spectrometry. Virology Journal, 2016, 13, 9.	3.4	9

#	Article	IF	Citations
37	VaSP1, catalytically active serine proteinase from Vipera ammodytes ammodytes venom with unconventional active site triad. Toxicon, 2014, 77, 93-104.	1.6	8
38	Factors influencing preclinicalin vivoevaluation of mumps vaccine strain immunogenicity. Human Vaccines and Immunotherapeutics, 2015, 11, 2446-2454.	3.3	7
39	Quality-Related Properties of Equine Immunoglobulins Purified by Different Approaches. Toxins, 2020, 12, 798.	3.4	7
40	Biological Activities and Proteomic Profile of the Venom of Vipera ursinii ssp., a very Rare Karst Viper from Croatia. Toxins, 2020, 12, 187.	3.4	7
41	Concept of sample-specific correction of immunoassay results for precise and accurate IgG quantification in horse plasma. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 276-282.	2.8	6
42	Use of Convective Interaction Media for Analysis of Longâ€Nosed Viper Venom. Journal of Liquid Chromatography and Related Technologies, 2007, 31, 38-53.	1.0	5
43	Comparison of mouse and rabbit model for the assessment of strong PGM-containing oil-based adjuvants. Veterinary Immunology and Immunopathology, 2008, 121, 232-240.	1.2	5
44	Optimization of tetanus toxoid ammonium sulfate precipitation process using response surface methodology. Preparative Biochemistry and Biotechnology, 2016, 46, 695-703.	1.9	5
45	Impact of complement and difference of cell-based assay and ELISA in determination of neutralization capacity against mumps and measles virus. Journal of Immunological Methods, 2021, 490, 112957.	1.4	5
46	Comparison of Preclinical Properties of Several Available Antivenoms in the Search for Effective Treatment of Vipera ammodytes and Vipera berus Envenoming. Toxins, 2021, 13, 211.	3.4	5
47	Generation of ammodytoxin-anti-cathepsin B immuno-conjugate as a model for delivery of secretory phospholipase A2 into cancer cells. Toxicon, 2008, 51, 754-764.	1.6	4
48	Dose dependent effects of standardized nose-horned viper (Vipera ammodytes ammodytes) venom on parameters of cardiac function in isolated rat heart. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2008, 147, 434-440.	2.6	4
49	Ammodytoxin content of Vipera ammodytes ammodytes venom as a prognostic factor for venom immunogenicity. Comparative Biochemistry and Physiology Part - C: Toxicology and Pharmacology, 2010, 151, 455-460.	2.6	4
50	Chromatography, mass spectrometry, and molecular modeling studies on ammodytoxins. Analytical and Bioanalytical Chemistry, 2012, 402, 2737-2748.	3.7	4
51	Streamlined downstream process for efficient and sustainable (Fab')2 antivenom preparation. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2020, 26, e20200025.	1.4	4
52	Purification and Characterization ofL,(L/D)â€Aminopeptidase from Guinea Pig Serum. Preparative Biochemistry and Biotechnology, 2006, 36, 175-195.	1.9	3
53	Intravenous Vipera berus Venom-Specific Fab Fragments and Intramuscular Vipera ammodytes Venom-Specific F(abâ€™)2 Fragments in Vipera ammodytes-Envenomed Patients. Toxins, 2021, 13, 279.	3.4	3
54	Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible?. Frontiers in Immunology, 2022, 13, 816159.	4.8	3

#	Article	IF	Citations
55	Roughness of Production Conditions: Does It Really Affect Stability of IgG-Based Antivenoms?. Toxins, 2022, 14, 483.	3.4	3
56	COVID-19 convalescent plasma therapy for immunodeficient patientsâ€“weighing up risks and benefits. Transfusion Clinique Et Biologique, 2021, 28, 424-425.	0.4	2
57	Development of Improved High-Performance Liquid Chromatography Method for the Determination of Residual Caprylic Acid in Formulations of Human Immunoglobulins. Molecules, 2022, 27, 1665.	3.8	2
58	Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks. Frontiers in Immunology, 2022, 13, .	4.8	2
59	Simple alternative to sialic acid determination in meningococcal polysaccharides W or Y. Journal of Pharmaceutical and Biomedical Analysis, 2016, 120, 283-289.	2.8	0
60	Comment on â€œAntivenom for European Vipera species envenomingâ€• Clinical Toxicology, 2018, 56, 909-910.	1.9	0
61	Challenges in antivenom downstream processing efficiency estimation. Toxicon, 2019, 159, S6.	1.6	0
62	Production- and Purification-Relevant Properties of Human and Murine Cytomegalovirus. Viruses, 2021, 13, 2481.	3.3	0